Introduction
Evotec SE today celebrated the grand opening of Building 95 (B95), its new biology facility located on the Dorothy Crowfoot Hodgkin Campus at Milton Park, Abingdon. Since acquiring Oxford Asymmetry International in 2000, Evotec has expanded its footprint in the region and is now one of the largest occupiers at Milton Park. B95 introduces cutting-edge bioprocessing and discovery capabilities designed to support the evolving needs of contract development and manufacturing organizations (CDMOs) engaged in biologics R&D and production.
Strategic Implications for CDMOs
The addition of B95 enhances Evotec’s service portfolio, offering CDMOs access to integrated biology and pharmacology platforms. Outsourcing partners can leverage the facility’s high-throughput screening, assay development, and early-stage cell line development under one roof. This vertical integration reduces handoff times between discovery and development phases, enabling streamlined workflows that can translate into faster project timelines and cost efficiencies for downstream manufacturing partners.
Facility Capabilities and Technology
B95 spans more than 2,500 square meters of laboratory and office space, featuring modular lab suites equipped for cell culture, molecular biology, and automation. Dedicated zones for high-content imaging and phenotypic screening accelerate lead identification and optimization. The facility includes cold rooms, containment areas, and a central automation hub with liquid-handling robotics to support reproducible, scalable processes critical to CDMO-scale production of biologics, such as monoclonal antibodies, cell therapies, and recombinant proteins.
Advanced Automation and Digitization
Evotec has invested heavily in laboratory automation and digital integration at B95. Automated sample management systems connect directly to a cloud-based data platform, providing real-time analytics and traceability. For CDMOs, this level of digitization enables remote monitoring of assay progress, data standardization across multiple sites, and seamless handoffs between discovery units and manufacturing teams. Such digital capabilities are increasingly essential as regulatory scrutiny of data integrity intensifies.
Regulatory and Quality Alignment
B95 has been designed to comply with international regulatory standards, including GMP guidelines for biologics research and early-stage manufacturing. Dedicated quality control and assurance units within the facility ensure that CDMO partners can validate critical assays, stability testing, and analytical method development in compliance with FDA, EMA, and MHRA requirements. Early integration of quality management systems reduces the risk of delays in clinical trials and regulatory submissions.
Supply Chain Optimization
By situating discovery, development, and analytical services within a single campus, Evotec enables CDMOs to minimize logistical complexity. Consolidated supply chains for reagents, consumables, and cold-chain transport lower the cost and risk associated with multi-vendor coordination. In addition, local warehousing and distribution capabilities at Milton Park facilitate rapid reagent replenishment and sample dispatch, which is critical for time-sensitive biologics projects.
Outsourcing and Partnership Opportunities
The launch of B95 positions Evotec as a collaborative partner for CDMOs seeking to expand or optimize their service offerings. Co-development agreements can tap into Evotec’s proprietary platforms for antibody discovery or target validation. Furthermore, small and mid-sized CDMOs lacking advanced molecular biology infrastructure can access state-of-the-art equipment and expertise on a fee-for-service basis, reducing capital expenditure and accelerating time to market.
Workforce Development and Talent Acquisition
The facility’s opening creates new opportunities for skilled scientists, engineers, and data analysts. Evotec plans to recruit experts in bioprocess development, bioinformatics, and regulatory affairs to support B95’s operations. For CDMOs, partnering with a site that fosters talent development offers a strategic advantage, ensuring a pipeline of trained personnel familiar with the latest technologies and best practices in biologics manufacturing.
Sustainability and Environmental Practices
B95 incorporates energy-efficient HVAC systems, LED lighting, and water-recycling processes to minimize environmental impact. Sustainable design reduces utility costs and supports corporate social responsibility goals for both Evotec and its CDMO clients. Increasingly, global pharmaceutical customers expect partners to demonstrate eco-friendly practices throughout the supply chain, and B95 sets a benchmark for green laboratory and process design.
Market Impact and Competitive Dynamics
The global biologics market is projected to grow at a CAGR of over 10% through 2028, driven by demand for novel antibody therapies, cell and gene therapies, and personalized medicine. Evotec’s B95 facility enhances capacity and breadth of services in a competitive CDMO landscape where speed, cost efficiency, and technical expertise are key differentiators. CDMOs that align with partners offering comprehensive discovery-to-development platforms can capture a larger share of the outsourcing market.
Future Outlook
Evotec plans further expansions on the Dorothy Crowfoot Hodgkin Campus, including additional suites for high-throughput bioproduction and downstream purification. As biologics pipelines become more complex, the ability to integrate early discovery with scalable development workflows will be critical. CDMOs that engage with integrated service providers like Evotec can better manage risk, control costs, and accelerate clinical timelines in an increasingly demanding regulatory environment.
Conclusion
The inauguration of Building 95 marks a significant milestone for Evotec and its CDMO partners. By offering state-of-the-art biology facilities, advanced automation, regulatory alignment, and sustainability features, Evotec strengthens its position as a strategic contract development and manufacturing partner. For CDMOs aiming to enhance their service capabilities and meet the evolving needs of the biologics market, collaboration with Evotec’s expanded Milton Park campus presents a compelling opportunity to drive innovation and growth.